QADA yields 3.82% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, QADA + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QADA + JNJ for your $10,000?
QAD Inc. provides cloud-based enterprise software solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers various software solutions, such as customer and service management solutions for manufacturers to acquire new customers; manufacturing solutions, which supports manufacturing business processes; enterprise asset management to manage, maintain, and install capital equipment; supply chain execution solutions that provides tools to support inventory and warehouse management; and financials solutions to manage and control finance and accounting processes. The company also provides demand and supply chain planning solutions to manage various procurement, manufacturing, inventory, distribution, and sales activities; global trade and transportation solutions to manage and optimize network of carriers for shipments; embedded analytics and business intelligence that offers data to measure performance; and internationalization, which supports companies that manufacture and distribute their products worldwide. In addition, it offers customer support and product update services, as well as professional services, including consulting, deployment, training, technical, development, and integration. The company markets its products through direct and indirect sales channels; and distributors and sales agents. It serves automotive, life sciences, consumer products, food and beverage, high technology, and industrial products manufacturing companies. QAD Inc. was founded in 1979 and is headquartered in Santa Barbara, California.
Full QADA Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.